Increased Plasma Endothelin in NIDDM Patients With Retinopathy

Makiko Kawamura; Hisako Ohgawara; Mitsuhide Naruse; Nobuhiro Suzuki; Naoko Iwasaki; Kiyoko Naruse; Sadao Hori; Hiroshi Demura; Yasue Omori

doi:10.2337/diacare.15.10.1396

Short Reports

Increased Plasma Endothelin in NIDDM Patients With Retinopathy

Makiko Kawamura, MD,
Hisako Ohgawara, MD,
Mitsuhide Naruse, MD,
Nobuhiro Suzuki, PHD,
Naoko Iwasaki, MD,
Kiyoko Naruse, MD,
Sadao Hori, MD,
Hiroshi Demura, MD and
Yasue Omori, MD

Diabetes Center, Department of Medicine, and Diabetic Ophthalmology, Institute of Clinical Endocrinology, Department of Medicine, Tokyo Women's Medical College Tokyo; and the Tsukuba Research Laboratories, Takeda Chemical Industries, Ltd. Tsukuba, Ibaraki, Japan

Address Correspondence and reprint requests to Dr. Makiko Kawamura, Department of Medicine, Diabetes Center, Tokyo Women's Medical College, 8–1 Kawadacho, Shinjuku-Ku, Tokyo 162, Japan.

Diabetes Care 1992 Oct; 15(10): 1396-1397. https://doi.org/10.2337/diacare.15.10.1396

Abstract

OBJECTIVE To elucidate the significance of ET in diabetic microvascular disease.

RESEARCH DESIGN AND METHODS We determined plasma levels of ir-ET-1 in 25 NIDDM patients without hypertension and/or renal dysfunction.

RESULTS The plasma levels of ir-ET-1 in NIDDM patients with simple (n = 8) and proliferative (n = 8) retinopathy were 0.58 ± 0.04 pM and 0.60 ± 0.04 pM, respectively, which were significantly higher than those in normal, nondiabetic subjects (0.24 ± 0.02 pM [n = 31]) and NIDDM patients without retinopathy (0.30 ± 0.05 pM [n = 9]).

CONCLUSIONS These results suggest that plasma ET-1 is related to diabetic microvascular disease.